Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients
2 other identifiers
observational
50
1 country
1
Brief Summary
Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS). And it is still unclear why cardiac biomarkers would increase in those patients. We hypothesized that excessive phosphorus is account for that phenomenon.To confirm that hypothesis,we used one phosphorus binder to reduce phosphorus absorption in hemodialysis patients for some time and observed the change of cardiac biomarkers of those patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2012
CompletedFirst Submitted
Initial submission to the registry
January 24, 2013
CompletedFirst Posted
Study publicly available on registry
January 31, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedMarch 17, 2015
November 1, 2014
4.5 years
January 24, 2013
March 14, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Reducing cardiac biomarkers in hemodialysis patients
6 months
Secondary Outcomes (1)
Improving cardiac function
1 year
Eligibility Criteria
The population will be selected from patients of nephrology department of Shanghai 10th people's hospital in Shanghai,China.
You may qualify if:
- Time of receiving hemodialysis is more than 1 year;
- Hyperphosphatemia before hemodialysis;
- Never use any phosphorus binder in the past 6 months.
You may not qualify if:
- Receiving coronary artery stent implantation before;
- Having any cardiovascular disease in the past 6 months;
- Cannot tolerate the side effects of phosphorus binder;
- Dose not take medicine according to the prescription;
- inadequate dialysis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai 10th People's Hospital
Shanghai, 200072, China
Biospecimen
serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ai Peng, Ph.D,M.D
Shanghai 10th People's Hospital of Tongji University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of the department of Nephrology, Shanghai 10th poeple's hospital
Study Record Dates
First Submitted
January 24, 2013
First Posted
January 31, 2013
Study Start
August 1, 2012
Primary Completion
February 1, 2017
Study Completion
June 1, 2018
Last Updated
March 17, 2015
Record last verified: 2014-11